{"id":"W4410421568","doi":"10.1016/j.jtho.2025.05.012","title":"Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Loxo Oncology; Chugai Pharmaceutical; Janssen Research and Development; EMD Serono; Manchester Clinical Research Facility; Genentech; LG Chem; Grifols; Pfizer Japan; Sociedad Española de Oncología Médica; Otsuka Pharmaceutical; Astellas Pharma; Eisai; Curtin University of Technology; Clovis Oncology; National Institute for Health and Care Research; BeiGene; Mirati Therapeutics; Revolution Medicines; Kissei; Johnson and Johnson; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Array BioPharma; Manchester Biomedical Research Centre; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Sanofi; Amgen; G1 Therapeutics; Jounce Therapeutics; Bayer Yakuhin; Celgene; AstraZeneca; Ignyta; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Exon; Lung cancer; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Mutation; Cancer research; Genetics; Gene; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002516602,0.0004817923,0.0007529247,0.0001438953,0.0002490147,0.000623454,0.0003580209,0.0005790948,0.001584843],"category_scores_gemma":[0.001257995,0.000179107,0.001129978,0.0002298753,0.0002224142,0.0003299425,0.000370949,0.0005557612,0.0003359797],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003635052,"about_ca_system_score_gemma":0.0005475712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001051732,"about_ca_topic_score_gemma":0.001950143,"domain_scores_codex":[0.9994088,0.0003047671,0.00004145154,0.0000840002,0.0001028123,0.00005813599],"domain_scores_gemma":[0.999036,0.0002169102,0.0002893785,0.0000853623,0.0001661125,0.0002062743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.445675,0.002982585,0.4228887,0.002155231,0.01055186,0.00037135,0.0006935863,0.0004745345,0.02597281,0.0002415535,0.004078968,0.08391395],"study_design_scores_gemma":[0.1002305,0.06469012,0.8104482,0.0002486761,0.01146073,0.0006412416,0.0003827267,0.0006616851,0.003683428,0.0002762451,0.007203079,0.00007340861],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930768,0.003528579,0.0001605736,0.0002079856,0.00002684942,0.0002749385,0.001742324,0.00001479233,0.0009671992],"genre_scores_gemma":[0.9959234,0.0008951618,0.0002893034,0.000204192,0.00004182459,0.0002739258,0.001875768,0.000005630565,0.0004909268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002516602,"threshold_uncertainty_score":0.01330918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0415045479709282,"score_gpt":0.4708750444098869,"score_spread":0.4293704964389586,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}